产品名称
Anti-erbB4 Antibody, clone HFR1/2G4, clone HFR1/2G4, from mouse
isotype
IgG1, kappa
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
HFR1/2G4, monoclonal
species reactivity
rat, human
species reactivity (predicted by homology)
mouse
technique(s)
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... ERBB4(2066)
Other Notes
Replaces: 04-348
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Purified
Purified mouse monoclonal IgM in 0.02 M PB with 0.25 M NaCl, pH 7.6, 0.01% Sodium Azide.
Preparation Note
Stable refrigerated at 2-8°C in undiluted aliquots for up to 1 year from date of receipt.
Analysis Note
Control
A431 cell lysate
A431 cell lysate
Routinely evaluated by Western Blot on A431 lysates.
Western Blot Analysis: 1:500 dilution of this lot detected C-ERB-4 on 10 μg of A431 lysates.
Western Blot Analysis: 1:500 dilution of this lot detected C-ERB-4 on 10 μg of A431 lysates.
Application
Detect erbB4 using this Anti-erbB4 Antibody, clone HFR1/2G4 validated for use in WB, IP, IH(P).
Immunoprecipitation: A previous lot of this antibody was used in IP.
Immunohistochemistry: Effective for formalin-fixed, paraffin-embedded sections.
Optimal working dilutions must be determined by end user.
Immunohistochemistry(paraffin): Representative testing from a previous lot.
Optimal Staining of erbB-4/HER-4 Monoclonal Antibody: DCIS and Pancreatic Cancer
Immunohistochemistry: Effective for formalin-fixed, paraffin-embedded sections.
Optimal working dilutions must be determined by end user.
Immunohistochemistry(paraffin): Representative testing from a previous lot.
Optimal Staining of erbB-4/HER-4 Monoclonal Antibody: DCIS and Pancreatic Cancer
Research Category
Signaling
Apoptosis & Cancer
Signaling
Apoptosis & Cancer
Research Sub Category
Growth Factors & Receptors
Growth Factors & Receptors
Biochem/physiol Actions
Reactive with human c-erB-4/Her 4 cytoplasmic domain of the protein (residues 1250-1264), a member of the EGF receptor (type 1) family involved in cell growth regulation. Expression or function may be altered in human cancers.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
v-ErbB was identified as the viral counterpart of the EGF Receptor, and its relatives have adopted this nomenclature (or the HER nomenclature for human proteins). These proteins are activated by Heregulin, Neuregulin and Amphiregulin. ErbB-2/HER-2, also known as neu, is amplified in large numbers of highly aggressive breast cancers, but all the family members are capable of heterodimerization, and together activate downstream signaling pathways. ErbB-3 has a natural "substitution" at the codon which is an invariant Lys residue at the ATP-binding site of all protein kinases. It is therefore inactive as a kinase, and can only become phosphorylated by heterodimerization with another erbB-family member. All members of this family, when Tyr-phosphorylated, can nucleate the formation of signaling complexes through adapter proteins.
~147 kDa
Immunogen
Epitope: Cytoplasmic domain of the protein, residues 1250-1264.
Synthetic peptide sequence RSTLQHPDYLQEYST from the cytoplasmic domain of the protein, residues 1250-1264.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Jody Fromm Longo et al.
Cell communication and signaling : CCS, 17(1), 74-74 (2019-07-12)
We have found that erbB receptor tyrosine kinases drive Ras hyperactivation and growth in NF1-null malignant peripheral nerve sheath tumors (MPNSTs). However, MPNSTs variably express multiple erbB receptors with distinct functional characteristics and it is not clear which of these
Jody Fromm Longo et al.
Journal of visualized experiments : JoVE, (174) (2021-09-14)
The development of new drugs that precisely target key proteins in human cancers is fundamentally altering cancer therapeutics. However, before these drugs can be used, their target proteins must be validated as therapeutic targets in specific cancer types. This validation
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持